Clear market notes built around the JSE, the rand, and what matters locally.

2026-08-28 15:31 • The Motley Fool Positive Axe Cap view: Selective

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with a lower 0.35% expense ratio and concentrated biotech focus, versus Invesco Pharmaceuticals ETF (PJP) with higher dividend yield and broader pharma exposure. Despite PJP's superior 5-year performance and lower volatility, the article concludes BBH is the better buy based on recent outperformance, though both funds offer targeted healthcare sector exposure with different risk-return profiles.

Axe note: VanEck Biotech’s focused growth beats Invesco Pharmaceuticals’ steady income, but both have distinct roles.

2026-08-28 15:30 • The Motley Fool Positive Axe Cap view: Selective

Peter Thiel's hedge fund Thiel Macro rebuilt a $419 million portfolio in Q2 2026, allocating roughly 33% across three energy stocks: Vista Energy, Vistra, and X-Energy. Thiel views electricity as the critical bottleneck for AI development rather than chips, positioning in nuclear and energy infrastructure to enable AI hyperscaler operations.

Axe note: Thiel’s stake in energy, especially nuclear, signals a shift from chips to power as AI’s real bottleneck.

2026-08-28 15:21 • The Motley Fool Negative Axe Cap view: Neutral

Dycom Industries shares plummeted 21.6% following Q2 2027 earnings despite beating revenue estimates. The decline was driven by a narrower adjusted EBITDA margin in the communications segment (13.6% vs 14.9% year-over-year) due to operational scaling investments, deferred wireless projects, and fuel cost pressures. Multiple analysts cut price targets, including KeyBanc (to $423 from $610) and Cantor Fitzgerald (to $476 from $654). However, the company achieved record backlog of $12.2 billion and strong free cash flow of $37.9 billion.

Axe note: Despite solid backlog and cash flow, Dycom’s profit margins and project delays spook investors.